We have begun evaluating CsA as a potential drug for inhibiting
photoreceptor cell loss through apoptosis. CsA blocks release of
cytochrome
c from mitochondria, which prevents activation of
caspase 9, acting upstream of caspase 3, the proximal caspase in the
apoptotic pathway.
39 40 When
rd retina was
exposed to 25 μg/ml CsA in 10% FBS medium, rescue from cell loss was
not observed. The dosage used in the current study was the same as the
one used to stop thyroid-induced apoptotic regression of the tadpole
tail.
40 However, in another study using T cells, apoptosis
has been effectively blocked using a 1-μg/ml concentration of
CsA.
41 Therefore, the dosage used in our experiment may
have been too high, inducing interference with the inhibition of
photoreceptor cell apoptosis. Söderpalm et al.
42 have reported recently that z-VAD-fmk, a broad-spectrum caspase
blocker, effectively stops retinoic acid-induced photoreceptor cell
death in vitro. Caspase-3 is activated in transgenic rats with opsin
mutation S334ter, and photoreceptor loss through apoptosis can be
delayed by intraocular injection with z-DEVD-fmk.
43 z-DEVD-fmk is a caspase-3–selective inhibitor. We did not observe
z-DEVD-fmk–induced rescue of mouse
rd cells in vitro. In a
preliminary study, Chong et al.
44 have injected several
caspase inhibitors into the vitreous of the retinal degeneration slow
(
rds) and
rd mice. They found only an effect of
the caspase-3 inhibitor III (Ac-DEVD-CMK) in the
rds mouse.
No significant effects have been found either from the other treatments
or in the
rd mouse. This is similar to our experience, which
supports the conclusion by Chong et al.
44 that the
protective effect by the caspase-3 inhibitors is ambiguous or better,
selective to specific mutations. Because little information is
currently available about retinal specificity, proper dosage, when to
begin therapy, and best delivery regimen for caspase inhibitors,
further studies are needed. In any case, the emerging picture from
these apoptosis blockers is relevant to the neurotrophic factor issue.
From the experimental drug treatments for inherited retinal
degeneration currently under investigation, CNTF, and BDNF rank as the
most potent and consistent broad-spectrum treatment when assayed in
vitro. This warrants taking the next step: an in vivo comparison of
this combination therapy against alternatives like
diltiazem.
45 It is from these systematic in vitro
screenings followed by in vivo testing that true successful
pharmacologic therapies for retinal degeneration will emerge.